# A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

> **NCT01597713** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 83 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Healthy

## Interventions

- **DRUG:** NNC 0148-0000-0362
- **DRUG:** insulin glargine
- **DRUG:** placebo
- **DRUG:** NNC 0148-0000-0362
- **DRUG:** NNC 0148-0000-0362
- **DRUG:** NNC 0148-0000-0362

## Key facts

- **NCT ID:** NCT01597713
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597713, "A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01597713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*